Suszek Dorota, Jeleniewicz Radosław, Majdan Maria
Katedra i Klinika Reumatologii i Układowych Chorób Tkanki Łącznej, Uniwersytet Medyczny, Lublin.
Postepy Hig Med Dosw (Online). 2012 Aug 22;66:568-73. doi: 10.5604/17322693.1007663.
The prevention of chronic organic damage and complete inhibition of inflammatory activity of the disease are the main goals in the treatment of systemic lupus erythematosus (SLE). Current therapies of SLE are not effective enough and they may cause various serious side effects. Biological therapies, affecting important pathogenetic disturbances in the immunological system of SLE patients, give hope for the development of a new treatment for SLE. Currently the most advanced clinical trials are being conducted with anti-lymphocyte B drugs, such as rituximab, belimumab and epratuzumab. Belimumab as the first biological agent was registered for treatment of the active, seropositive form of SLE. The advances in immunology and rheumatology nowadays raise the hope of finding effective and safe treatment for SLE. In our article we present an overview of data concerning perspectives of biological treatment in SLE.
预防慢性器质性损害以及完全抑制该疾病的炎症活动是系统性红斑狼疮（SLE）治疗的主要目标。目前SLE的治疗方法效果不够显著，且可能会引发各种严重的副作用。生物疗法针对SLE患者免疫系统中的重要致病紊乱，为SLE新疗法的开发带来了希望。目前正在使用抗淋巴细胞B药物（如利妥昔单抗、贝利木单抗和依帕珠单抗）进行最先进的临床试验。贝利木单抗作为首个生物制剂已获批用于治疗活动性、血清学阳性的SLE。当今免疫学和风湿病学的进展增加了找到有效且安全的SLE治疗方法的希望。在我们的文章中，我们概述了有关SLE生物治疗前景的数据。
